Holen Sie sich die Stockscreener-App
20.98
2.96%
-0.64
Handel nachbörslich:
20.60
-0.38
-1.81%
Schlusskurs vom Vortag:
$21.62
Offen:
$21.5
24-Stunden-Volumen:
3.00M
Relative Volume:
0.93
Marktkapitalisierung:
$3.03B
Einnahmen:
$62.38M
Nettoeinkommen (Verlust:
$-101.59M
KGV:
-24.27
EPS:
-0.8644
Netto-Cashflow:
$-139.93M
1W Leistung:
-18.59%
1M Leistung:
-1.13%
6M Leistung:
+158.69%
1J Leistung:
+1,388%
1-Tages-Spanne:
$20.76
$22.23
1-Wochen-Bereich:
$20.76
$27.12
52-Wochen-Spanne:
$1.03
$28.41
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
20.98 | 3.03B | 62.38M | -101.59M | -139.93M | -0.8644 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-23 | Eingeleitet | Mizuho | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Tango Therapeutics (TNGX) director receives RSU and option grants as board compensation - Stock Titan
TNGX (NASDAQ: TNGX) affiliate files to sell 65,460 shares after option exercise - Stock Titan
Tango Therapeutics (TNGX) price target increased by 32.09% to 20.06 - MSN
The Nasdaq Biotechnology Index closed down more than 1.2%. Among its constituent stocks, Tango Therapeutics fell by 12.25%, Personalis dropped 8.36%, PTC Therapeutics decreased by 8.13%, Foghorn slid 8.12%, and Erasca declined 7.98%. - Bitget
Tango Therapeutics (NASDAQ:TNGX) Trading Down 9.7%Here's What Happened - MarketBeat
Tango Therapeutics (TNGX) price target increased by 11.68% to 24.38 - MSN
Tango Therapeutics is the best performing healthcare stock in March - MSN
How New C-Suite Hires At Tango Therapeutics (TNGX) Have Changed Its Investment Story - simplywall.st
Stifel raises Tango Therapeutics stock price target on drug combo potential - Investing.com UK
Stifel raises Tango Therapeutics stock price target on drug combo potential By Investing.com - Investing.com South Africa
Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect? - MSN
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
[Form 3] Tango Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
CFO Matthew Gall (TNGX) files Form 3 with no reported trades - Stock Titan
TNGX News | TANGO THERAPEUTICS INC (NASDAQ:TNGX) - ChartMill
TNGX Financials: Income Statement, Balance Sheet & Cash Flow | Tango Therapeutics Inc - Stock Titan
Tango Therapeutics stock hits all-time high at 27.16 USD By Investing.com - Investing.com Australia
Tango Therapeutics stock hits all-time high at 27.16 USD - Investing.com
354,192 Shares in Tango Therapeutics, Inc. $TNGX Bought by Mass General Brigham Inc - MarketBeat
Stifel reiterates Tango Therapeutics stock rating on combo potential By Investing.com - Investing.com Australia
Stifel reiterates Tango Therapeutics stock rating on combo potential - Investing.com
HBS1L degradation inducers named in Tango Therapeutics patent - BioWorld News
Is Tango Therapeutics’ New Leadership Bench Reframing Its R&D Ambitions or Its Risk Profile (TNGX)? - simplywall.st
Tango Therapeutics (TNGX) Stock Stop Loss (Eye on Rally) 2026-04-18Stock Ideas - UBND thành phố Hải Phòng
Is Tango Therapeutics (TNGX) Building the Right Leadership Mix to Navigate Complex Oncology Pipelines? - Yahoo Finance
Tango Therapeutics (NASDAQ: TNGX) details 2026 virtual meeting, director elections and pay vote - Stock Titan
[ARS] Tango Therapeutics, Inc. SEC Filing - Stock Titan
Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 38,460 Shares of Stock - MarketBeat
Tango Therapeutics president sells $961k in stock By Investing.com - Investing.com Canada
Tango Therapeutics president sells $961k in stock - Investing.com
Tango Therapeutics (TNGX) R&D president exercises options and sells stock - Stock Titan
Tudor Investment Corp ET AL Acquires New Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat - Sahm
Tango Therapeutics Overhauls Finance Leadership Amid Clinical Push - TipRanks
Tango Therapeutics names Matthew Gall as chief financial officer By Investing.com - Investing.com South Africa
New CFO and senior leaders join Tango Therapeutics (NASDAQ: TNGX) - Stock Titan
Tango Therapeutics names Matthew Gall as chief financial officer - Investing.com
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tango Therapeutics Inc-Aktie (TNGX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Crystal Adam | President, R&D |
Apr 15 '26 |
Option Exercise |
5.20 |
38,460 |
199,992 |
151,082 |
| Crystal Adam | President, R&D |
Apr 15 '26 |
Sale |
25.00 |
38,460 |
961,500 |
112,622 |
| Crystal Adam | President, R&D |
Apr 01 '26 |
Option Exercise |
5.20 |
27,000 |
140,400 |
139,622 |
| Crystal Adam | President, R&D |
Apr 01 '26 |
Sale |
21.20 |
27,000 |
572,478 |
112,622 |
| Crystal Adam | President, R&D |
Mar 25 '26 |
Option Exercise |
5.20 |
12,000 |
62,400 |
124,622 |
| Crystal Adam | President, R&D |
Mar 25 '26 |
Sale |
20.11 |
12,000 |
241,320 |
112,622 |
2.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):